Home > Journals > Medicine > European Journal of Dermatology > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Retinoic‐acid receptor β expression in melanocytes


European Journal of Dermatology. Volume 14, Number 1, 19-23, January-February 2004, Investigative report

Free Article  

Author(s) : Nelly BOEHM, Brigitte SAMAMA, Bernard CRIBIER, Cécile ROCHETTE‐EGLY

Summary : Retinoic acid receptors (RAR) and retinoic X receptors (RXR) are critical for skin homeostasis. In epidermis, RXRα and RARγ isoforms are highly expressed but only weak or no expression of RARβ has been reported. Here, we re‐examined RARβ in situ expression in comparison with that of the RXRα, in both normal skin and melanocytic tumours. In normal skin, RXRα was localized in epidermis, sebaceous glands and hair follicles, while RARβ was detectable only in melanocytes and in stratum granulosum. RXRα was never detected in melanocytic tumours, neither in nevi, nor in melanomas. RARβ was also absent from melanoma cells but was present in nevus cells. These results indicate that melanoma are characterised by simultaneous decrease of RARβ and absence of RXRα that may be responsible for the RA‐resistance of most melanoma cell lines.

Keywords : Immunocytochemistry, melanocyte, melanoma, retinoic acid receptors, RXRα, RARβ

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]